HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,547,134 | -19.6% | 328,459 | -24.1% | 1.70% | -11.0% |
| Q2 2023 | $15,614,018 | -4.6% | 432,881 | +1.0% | 1.91% | -8.8% |
| Q1 2023 | $16,367,088 | -34.9% | 428,570 | -3.0% | 2.09% | -37.9% |
| Q4 2022 | $25,138,932 | +42.5% | 441,809 | -1.0% | 3.37% | +42.0% |
| Q3 2022 | $17,637,000 | -26.8% | 446,049 | -18.5% | 2.37% | -11.4% |
| Q2 2022 | $24,085,000 | +65.6% | 547,381 | +50.1% | 2.68% | +94.3% |
| Q1 2022 | $14,545,000 | -1.4% | 364,718 | -0.6% | 1.38% | +18.3% |
| Q4 2021 | $14,753,000 | -41.5% | 366,897 | -40.8% | 1.16% | -44.7% |
| Q3 2021 | $25,212,000 | +3.1% | 619,766 | +15.1% | 2.11% | +6.8% |
| Q2 2021 | $24,460,000 | +8.1% | 538,656 | -0.8% | 1.97% | -0.8% |
| Q1 2021 | $22,628,000 | -16.1% | 542,764 | -14.1% | 1.99% | -13.5% |
| Q4 2020 | $26,984,000 | +71.9% | 631,807 | +5.7% | 2.30% | +73.4% |
| Q3 2020 | $15,702,000 | +31.3% | 597,477 | +33.9% | 1.32% | +25.3% |
| Q2 2020 | $11,959,000 | – | 446,070 | – | 1.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 1,129,551 | $47,091,000 | 6.38% |
| First Light Asset Management, LLC | 2,011,350 | $83,853,000 | 5.56% |
| TRAN CAPITAL MANAGEMENT, L.P. | 1,353,208 | $56,415,000 | 5.03% |
| SNYDER CAPITAL MANAGEMENT L P | 2,920,860 | $121,771,000 | 3.50% |
| DOHENY ASSET MANAGEMENT /CA | 120,028 | $5,004,000 | 3.39% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 104,945 | $4,375,000 | 2.39% |
| Redwood Investments, LLC | 542,764 | $22,628,000 | 1.99% |
| Kent Lake Capital LLC | 85,000 | $3,544,000 | 1.44% |
| Lisanti Capital Growth, LLC | 263,460 | $10,984,000 | 1.41% |
| Bellevue Group AG | 3,011,966 | $125,569,000 | 1.33% |